Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Braun, M.M.; Overbeek-Wager, E.A.; Grumbo, R.J. Diagnosis and Management of Endometrial Cancer. Am. Fam. Physician 2016, 93, 468–474. [Google Scholar] [PubMed]
- Onstad, M.A.; Schmandt, R.E.; Lu, K.H. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016, 34, 4225–4230. [Google Scholar] [CrossRef]
- Ray-Coquard, I.; Favier, L.; Weber, B.; Roemer-Becuwe, C.; Bougnoux, P.; Fabbro, M.; Floquet, A.; Joly, F.; Plantade, A.; Paraiso, D.; et al. Everolimus as Second- or Third-Line Treatment of Advanced Endometrial Cancer: ENDORAD, a Phase II Trial of GINECO. Br. J. Cancer 2013, 108, 1771–1777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hutt, S.; Tailor, A.; Ellis, P.; Michael, A.; Butler-Manuel, S.; Chatterjee, J. The Role of Biomarkers in Endometrial Cancer and Hyperplasia: A Literature Review. Acta Oncol. Stockh. Swed. 2019, 58, 342–352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bagaria, M.; Shields, E.; Bakkum-Gamez, J.N. Novel Approaches to Early Detection of Endometrial Cancer. Curr. Opin. Obstet. Gynecol. 2017, 29, 40–46. [Google Scholar] [CrossRef] [PubMed]
- Rižner, T.L. Discovery of Biomarkers for Endometrial Cancer: Current Status and Prospects. Expert Rev. Mol. Diagn. 2016, 16, 1315–1336. [Google Scholar] [CrossRef]
- Njoku, K.; Chiasserini, D.; Whetton, A.D.; Crosbie, E.J. Proteomic Biomarkers for the Detection of Endometrial Cancer. Cancers 2019, 11, 1572. [Google Scholar] [CrossRef] [Green Version]
- Panici, P.B.; Scambia, G.; Baiocchi, G.; Perrone, L.; Greggi, S.; Battaglia, F.; Mancuso, S. Multiple Serum Markers in Patients with Endometrial Cancer. Gynecol. Obstet. Investig. 1989, 27, 208–212. [Google Scholar] [CrossRef]
- Scambia, G.; Gadducci, A.; Panici, P.B.; Foti, E.; Ferdeghini, M.; Ferrandina, G.; Amoroso, M.; Castellani, C.; Facchini, V.; Mancuso, S. Combined Use of CA 125 and CA 15-3 in Patients with Endometrial Carcinoma. Gynecol. Oncol. 1994, 54, 292–297. [Google Scholar] [CrossRef]
- Kanat-Pektas, M.; Yenicesu, O.; Gungor, T.; Bilge, U. Predictive Power of Sexual Hormones and Tumor Markers in Endometrial Cancer. Arch. Gynecol. Obstet. 2010, 281, 709–715. [Google Scholar] [CrossRef]
- Wang, Y.; Cao, R.; Jin, H.; Huang, Y.; Zhang, X.; Cong, Q.; He, Y.; Xu, C. Altered Protein Expression in Serum from Endometrial Hyperplasia and Carcinoma Patients. J. Hematol. Oncol. 2011, 4, 15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cocco, E.; Bellone, S.; El-Sahwi, K.; Cargnelutti, M.; Buza, N.; Tavassoli, F.A.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Serum Amyloid A: A Novel Biomarker for Endometrial Cancer. Cancer 2010, 116, 843–851. [Google Scholar] [CrossRef]
- Omer, B.; Genc, S.; Takmaz, O.; Dirican, A.; Kusku-Kiraz, Z.; Berkman, S.; Gurdol, F. The Diagnostic Role of Human Epididymis Protein 4 and Serum Amyloid-A in Early-Stage Endometrial Cancer Patients. Tumour Biol. 2013, 34, 2645–2650. [Google Scholar] [CrossRef]
- Tarney, C.M.; Wang, G.; Bateman, N.W.; Conrads, K.A.; Zhou, M.; Hood, B.L.; Loffredo, J.; Tian, C.; Darcy, K.M.; Hamilton, C.A.; et al. Biomarker Panel for Early Detection of Endometrial Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am. J. Obstet. Gynecol. 2019, 221, 472.e1–472.e10. [Google Scholar] [CrossRef]
- Zhu, J.; Shu, X.; Guo, X.; Liu, D.; Bao, J.; Milne, R.L.; Giles, G.G.; Wu, C.; Du, M.; White, E.; et al. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Cancer Epidemiol. Biomark. 2020, 29, 1501–1508. [Google Scholar] [CrossRef]
- Sun, B.B.; Maranville, J.C.; Peters, J.E.; Stacey, D.; Staley, J.R.; Blackshaw, J.; Burgess, S.; Jiang, T.; Paige, E.; Surendran, P.; et al. Genomic Atlas of the Human Plasma Proteome. Nature 2018, 558, 73–79. [Google Scholar] [CrossRef]
- O’Mara, T.A.; Glubb, D.M.; Amant, F.; Annibali, D.; Ashton, K.; Attia, J.; Auer, P.L.; Beckmann, M.W.; Black, A.; Bolla, M.K.; et al. Identification of Nine New Susceptibility Loci for Endometrial Cancer. Nat. Commun. 2018, 9, 3166. [Google Scholar] [CrossRef]
- Burgess, S.; Butterworth, A.; Thompson, S.G. Mendelian Randomization Analysis with Multiple Genetic Variants Using Summarized Data. Genet. Epidemiol. 2013, 37, 658–665. [Google Scholar] [CrossRef] [Green Version]
- Wu, L.; Shu, X.; Bao, J.; Guo, X.; Kote-Jarai, Z.; Haiman, C.A.; Eeles, R.A.; Zheng, W. PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. Cancer Res. 2019, 79, 4592–4598. [Google Scholar] [CrossRef] [PubMed]
- Shu, X.; Bao, J.; Wu, L.; Long, J.; Shu, X.-O.; Guo, X.; Yang, Y.; Michailidou, K.; Bolla, M.K.; Wang, Q.; et al. Evaluation of Associations between Genetically Predicted Circulating Protein Biomarkers and Breast Cancer Risk. Int. J. Cancer 2020, 146, 2130–2138. [Google Scholar] [CrossRef] [PubMed]
- Krämer, A.; Green, J.; Pollard, J.; Tugendreich, S. Causal Analysis Approaches in Ingenuity Pathway Analysis. Bioinforma. Oxf. Engl. 2014, 30, 523–530. [Google Scholar] [CrossRef]
- Lim, D.; Oliva, E. Nonendometrioid Endometrial Carcinomas. Semin. Diagn. Pathol. 2010, 27, 241–260. [Google Scholar] [CrossRef] [PubMed]
- Martinez-Garcia, E.; Lopez-Gil, C.; Campoy, I.; Vallve, J.; Coll, E.; Cabrera, S.; Ramon, Y.; Cajal, S.; Matias-Guiu, X.; Van Oostrum, J.; et al. Advances in Endometrial Cancer Protein Biomarkers for Use in the Clinic. Expert Rev. Proteom. 2018, 15, 81–99. [Google Scholar] [CrossRef]
- Chrysovergis, K.; Wang, X.; Kosak, J.; Lee, S.-H.; Kim, J.S.; Foley, J.F.; Travlos, G.; Singh, S.; Baek, S.J.; Eling, T.E. NAG-1/GDF-15 Prevents Obesity by Increasing Thermogenesis, Lipolysis and Oxidative Metabolism. Int. J. Obes. 2014, 38, 1555–1564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kyrgios, I.; Galli-Tsinopoulou, A.; Stylianou, C.; Papakonstantinou, E.; Arvanitidou, M.; Haidich, A.-B. Elevated Circulating Levels of the Serum Acute-Phase Protein YKL-40 (Chitinase 3-like Protein 1) Are a Marker of Obesity and Insulin Resistance in Prepubertal Children. Metabolism 2012, 61, 562–568. [Google Scholar] [CrossRef] [PubMed]
- Hempen, M.; Kopp, H.-P.; Elhenicky, M.; Höbaus, C.; Brix, J.-M.; Koppensteiner, R.; Schernthaner, G.; Schernthaner, G.-H. YKL-40 Is Elevated in Morbidly Obese Patients and Declines after Weight Loss. Obes. Surg. 2009, 19, 1557–1563. [Google Scholar] [CrossRef]
- Shaw, E.; Farris, M.; McNeil, J.; Friedenreich, C. Obesity and Endometrial Cancer. Recent Results Cancer Res. 2016, 208, 107–136. [Google Scholar] [CrossRef] [PubMed]
- O’Mara, T.A.; Spurdle, A.B.; Glubb, D.M. Endometrial Cancer Association Consortium Endometrial Cancer Association Consortium Analysis of Promoter-Associated Chromatin Interactions Reveals Biologically Relevant Candidate Target Genes at Endometrial Cancer Risk Loci. Cancers 2019, 11, 1440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fitau, J.; Boulday, G.; Coulon, F.; Quillard, T.; Charreau, B. The Adaptor Molecule Lnk Negatively Regulates Tumor Necrosis Factor-Alpha-Dependent VCAM-1 Expression in Endothelial Cells through Inhibition of the ERK1 and -2 Pathways. J. Biol. Chem. 2006, 281, 20148–20159. [Google Scholar] [CrossRef] [Green Version]
- Kullo, I.J.; Shameer, K.; Jouni, H.; Lesnick, T.G.; Pathak, J.; Chute, C.G.; de Andrade, M. The ATXN2-SH2B3 Locus Is Associated with Peripheral Arterial Disease: An Electronic Medical Record-Based Genome-Wide Association Study. Front. Genet. 2014, 5, 166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Romanowicz-Makowska, H.; Smolarz, B.; Połać, I.; Sporny, S. Single Nucleotide Polymorphisms of RAD51 G135C, XRCC2 Arg188His and XRCC3 Thr241Met Homologous Recombination Repair Genes and the Risk of Sporadic Endometrial Cancer in Polish Women: Polymorphism of RAD51, XRCC2 and XRCC3 and Endometrial Cancer. J. Obstet. Gynaecol. Res. 2012, 38, 918–924. [Google Scholar] [CrossRef]
- Michalska, M.M.; Samulak, D.; Romanowicz, H.; Smolarz, B. Association of Polymorphisms in the 5’ Untranslated Region of RAD51 Gene with Risk of Endometrial Cancer in the Polish Population. Arch. Gynecol. Obstet. 2014, 290, 985–991. [Google Scholar] [CrossRef]
- Krupa, R.; Sobczuk, A.; Popławski, T.; Wozniak, K.; Blasiak, J. DNA Damage and Repair in Endometrial Cancer in Correlation with the HOGG1 and RAD51 Genes Polymorphism. Mol. Biol. Rep. 2011, 38, 1163–1170. [Google Scholar] [CrossRef] [Green Version]
- Tsukazaki, K.; Sakayori, M.; Arai, H.; Yamaoka, K.; Kurihara, S.; Nozawa, S. Abnormal Expression of Blood Group-Related Antigens in Uterine Endometrial Cancers. Jpn. J. Cancer Res. GANN 1991, 82, 934–941. [Google Scholar] [CrossRef]
- Xu, W.-H.; Zheng, W.; Xiang, Y.-B.; Shu, X.-O. ABO Blood Type Is Associated with Endometrial Cancer Risk in Chinese Women. Chin. J. Cancer 2011, 30, 766–771. [Google Scholar] [CrossRef] [PubMed]
- Yuzhalin, A.E.; Kutikhin, A.G. ABO and Rh Blood Groups in Relation to Ovarian, Endometrial and Cervical Cancer Risk among the Population of South-East Siberia. Asian Pac. J. Cancer Prev. APJCP 2012, 13, 5091–5096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abu-Zaid, A.; Alsabban, M.; Abuzaid, M.; Alomar, O.; Al-Badawi, I.A.; Salem, H. ABO Blood Group and Endometrial Carcinoma: A Preliminary Single-Center Experience from Saudi Arabia. Cureus 2017, 9, e1959. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schlosser, P.; Li, Y.; Sekula, P.; Raffler, J.; Grundner-Culemann, F.; Pietzner, M.; Cheng, Y.; Wuttke, M.; Steinbrenner, I.; Schultheiss, U.T.; et al. Genetic Studies of Urinary Metabolites Illuminate Mechanisms of Detoxification and Excretion in Humans. Nat. Genet. 2020, 52, 167–176. [Google Scholar] [CrossRef]
- Kim, S.K. Identification of 613 New Loci Associated with Heel Bone Mineral Density and a Polygenic Risk Score for Bone Mineral Density, Osteoporosis and Fracture. PLoS ONE 2018, 13, e0200785. [Google Scholar] [CrossRef] [Green Version]
- Kichaev, G.; Bhatia, G.; Loh, P.-R.; Gazal, S.; Burch, K.; Freund, M.K.; Schoech, A.; Pasaniuc, B.; Price, A.L. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. Am. J. Hum. Genet. 2019, 104, 65–75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Warrington, N.M.; Beaumont, R.N.; Horikoshi, M.; Day, F.R.; Helgeland, Ø.; Laurin, C.; Bacelis, J.; Peng, S.; Hao, K.; Feenstra, B.; et al. Maternal and Fetal Genetic Effects on Birth Weight and Their Relevance to Cardio-Metabolic Risk Factors. Nat. Genet. 2019, 51, 804–814. [Google Scholar] [CrossRef] [PubMed]
Protein | Protein Full Name | Protein-Encoding Gene | Region for Protein Encoding Gene | Instrument Variants | Type of pQTL | OR a | Lower Bound 95% CI a | Upper Bound 95% CI a | p-Value | FDR p-Value b | p-Value after Conditioning on Risk Variants c |
---|---|---|---|---|---|---|---|---|---|---|---|
VCAM-1 | Vascular cell adhesion protein 1 | VCAM1 | 1p21.2 | rs3184504 | trans | 0.60 | 0.51 | 0.70 | 1.14 × 10−10 | 1.53 × 10−7 | NA |
RA51D | DNA repair protein RAD51 homolog 4 | RAD51D | 17q12 | rs6838228; rs45446698 | trans; trans | 1.21 | 1.13 | 1.30 | 2.46 × 10−8 | 1.66 × 10−5 | 2.46 × 10−8 |
Desmoglein-2 | Desmoglein-2 | DSG2 | 18q12.1 | rs687621; rs2704050 | trans; cis | 1.27 | 1.14 | 1.42 | 2.18 × 10−5 | 0.01 | 2.18 × 10−5 |
MICB | MHC class I polypeptide-related sequence B | MICB | 6p21.33 | rs3134900 | cis | 1.14 | 1.07 | 1.22 | 3.30 × 10−5 | 0.01 | 2.41 × 10−5 |
BGAT | Histo-blood group ABO system transferase | ABO | 9q34.2 | rs505922 | cis | 1.05 | 1.02 | 1.08 | 8.50 × 10−5 | 0.02 | 8.51 × 10−5 |
Alkaline phosphatase intestine | Intestinal-type alkaline phosphatase | ALPI | 2q37.1 | rs550057 | trans | 0.77 | 0.68 | 0.89 | 1.84 × 10−4 | 3.54 × 10−2 | 1.84 × 10−4 |
ST4S6 | Carbohydrate sulfotransferase 15 | CHST15 | 10q26.13 | rs550057 | trans | 0.82 | 0.74 | 0.91 | 1.84 × 10−4 | 3.54 × 10−2 | 1.84 × 10−4 |
GLCE | D-glucuronyl C5-epimerase | GLCE | 15q23 | rs2519093; rs11854180 | trans; cis | 1.07 | 1.03 | 1.11 | 2.14 × 10−4 | 3.61 × 10−2 | 2.14 × 10−4 |
DC-SIGN | CD209 antigen | CD209 | 19p13.2 | rs505922; rs145827860 | trans; cis | 1.07 | 1.03 | 1.10 | 3.04 × 10−4 | 4.56 × 10−2 | 3.04 × 10−4 |
Protein | Endometrioid (8758 Cases/46 126 Controls) | Non-Endometrioid (1230 Cases/35 447 Controls) | ||||||
---|---|---|---|---|---|---|---|---|
OR a | Lower Bound 95% CI a | Upper Bound 95% CI a | p-Value | OR a | Lower Bound 95% CI a | Upper Bound 95% CI a | p-Value | |
VCAM-1 | 0.58 | 0.48 | 0.69 | 5.78 × 10−9 | 0.58 | 0.37 | 0.91 | 1.89 × 10−2 |
RA51D | 1.19 | 1.10 | 1.30 | 1.87 × 10−5 | NA b | NA b | NA b | NA b |
Desmoglein-2 | 1.21 | 1.06 | 1.38 | 4.09 × 10−3 | 1.35 | 0.98 | 1.85 | 6.84 × 10−2 |
MICB | 1.15 | 1.07 | 1.24 | 2.96 × 10−4 | 1.04 | 0.86 | 1.24 | 0.70 |
BGAT | 1.04 | 1.01 | 1.07 | 1.11 × 10−2 | 1.09 | 1.01 | 1.16 | 1.82 × 10−2 |
Alkaline phosphatase intestine | 0.84 | 0.71 | 0.98 | 2.46 × 10−2 | 0.61 | 0.42 | 0.90 | 1.14 × 10−2 |
ST4S6 | 0.87 | 0.77 | 0.98 | 2.46 × 10−2 | 0.68 | 0.51 | 0.92 | 1.14 × 10−2 |
GLCE | 1.07 | 1.02 | 1.12 | 2.14 × 10−3 | 0.99 | 0.89 | 1.09 | 0.78 |
DC-SIGN | 1.05 | 1.00 | 1.09 | 3.16 × 10−2 | 1.13 | 1.02 | 1.25 | 1.68 × 10−2 |
Top Canonical Pathways | Top Diseases and Disorders | Molecular and Cellular Functions | Top Networks | ||
---|---|---|---|---|---|
p-Value | Involved Molecules | ||||
Heparan Sulfate Biosynthesis (Late Stages); | 3.41 × 10−4 | CHST15, GLCE | Infectious diseases; cancer; cardiovascular disease; connective tissue disorders; hereditary disorder. | Cell-to-cell signaling and interaction; cellular movement; cellular assembly and organization; carbohydrate metabolism; cell morphology. | Cell-to-cell signaling and interaction, cancer, connective tissue disorders. |
Heparan Sulfate Biosynthesis; | 4.12 × 10−4 | CHST15, GLCE | |||
Crosstalk between Dendritic Cells and Natural Killer Cells; | 5.36 × 10−4 | CD209, MICB | |||
Dermatan Sulfate Biosynthesis (Late Stages); | 1.81 × 10−2 | CHST15 | |||
Chondroitin Sulfate Biosynthesis (Late Stages); | 1.88 × 10−2 | CHST15 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhu, J.; O’Mara, T.A.; Liu, D.; Setiawan, V.W.; Glubb, D.; Spurdle, A.B.; Fasching, P.A.; Lambrechts, D.; Buchanan, D.; Kho, P.F.; et al. Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers 2021, 13, 2088. https://doi.org/10.3390/cancers13092088
Zhu J, O’Mara TA, Liu D, Setiawan VW, Glubb D, Spurdle AB, Fasching PA, Lambrechts D, Buchanan D, Kho PF, et al. Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers. 2021; 13(9):2088. https://doi.org/10.3390/cancers13092088
Chicago/Turabian StyleZhu, Jingjing, Tracy A. O’Mara, Duo Liu, Veronica Wendy Setiawan, Dylan Glubb, Amanda B. Spurdle, Peter A. Fasching, Diether Lambrechts, Daniel Buchanan, Pik Fang Kho, and et al. 2021. "Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk" Cancers 13, no. 9: 2088. https://doi.org/10.3390/cancers13092088